HCG: Risks & Legal Status

Critical Safety Information#

HCG is a research compound that has not been approved for human use by any major regulatory agency. This page provides risk information for educational purposes only.

Growth Factor and Angiogenesis Risks#

We summarize three domains of safety risks for exogenous hCG: growth factor/angiogenic and tumor-biology concerns; immune-modulation risks; and quality-control issues in sourcing and compounding. A compact evidence table is embedded below to aid review.

Growth factor and angiogenic/tumor-biology risks

• Angiogenesis and VEGF/EGFR cross-talk: hCG, particularly hyperglycosylated hCG (hCG-H), can activate angiogenic programs, including cAMP-responsive elements in VEGF promoters, and induce amphiregulin that engages EGFR-family signaling, linking hCG to vascular remodeling and steroidogenic environments that support proliferation. These mechanisms suggest potential to enhance tumor angiogenesis or growth in LHCGR-expressing contexts.
• Isoform-dependent proliferative signaling: hCG exists as diverse glycoforms. hCG-H, produced by extravillous trophoblasts and by some tumors, shows lower steroidogenic but greater proliferative/angiogenic potential than classical hCG, and tumor-associated hCG variants/free β-hCG are linked to malignancies and may act as tumor markers or promoters (though some findings were confounded by TGFβ contamination in older preparations). Such isoform differences can alter safety profiles with exogenous dosing.
• Receptor signaling and mitogenic pathways: hCG can engage ERK1/2 and PI3K/AKT, and receptor cross-talk/heteromers may bias toward survival/proliferation signaling in vitro, providing a plausible route for tumor-supportive effects, albeit with some uncertainty on in vivo magnitude. Associations between hCG pathways and ovarian cancer features have been reported, reinforcing vigilance around neoplastic contexts.

Immune modulation risks

• Treg/Th17 balance and infection tolerance: Exogenous hCG increases Treg frequency via LH/CGR and can reprogram Th17 cells toward anti-inflammatory phenotypes; Th17 cells are important for defense against extracellular bacteria/fungi. Thus, hCG-driven shifts may dampen needed inflammatory responses and could, in theory, impair antimicrobial defense or anti-tumor immunity.
• Tolerogenic dendritic cells and cytokine suppression: hCG renders dendritic cells tolerogenic (reduced MHC-II/CD80/CD86; IDO induction) and suppresses proinflammatory cytokines (e.g., TNFα, IFNγ, IL-6), favoring regulatory milieus that may trade off with effective pathogen clearance and tumor surveillance.
• NK and B-cell modulation: hCG dose-dependently expands uterine NK cells via the mannose receptor and modulates B cells, including increases in regulatory/IL-10–producing subsets; while these actions support fetal tolerance, they may also increase systemic immunoregulation that, depending on exposure and context, could blunt cytotoxic or proinflammatory host defense.

Quality control and sourcing risks

• Potency variability and glycoform heterogeneity: Compounded hormones have shown wide potency deviations (e.g., 68%–268% of labeled active ingredient), and therapeutic hCG/LH products inherently comprise mixed glycoforms due to manufacturing, which can shift bioactivity and safety profiles. Robust, orthogonal potency assays and glycoform characterization are critical.
• Sterility/contamination and regulatory gaps: Historical compounding lapses highlight risks of contamination and sterility failures; contaminants such as TGFβ have confounded hCG bioactivity in research settings and underscore the need for GMP-compliant outsourcing facilities with adverse event reporting. Access challenges and mixed oversight across 503A vs 503B facilities further complicate product quality assurance for hCG.

Overall assessment Exogenous hCG is mechanistically capable of driving angiogenesis and proliferative signaling via VEGF/EGFR cross-talk and biased receptor signaling; it reshapes immune responses toward tolerance by expanding Tregs, reprogramming Th17, and inducing tolerogenic dendritic cells, with plausible trade-offs for infection control and tumor immunity; and it carries quality-control risks when sourced from compounded or heterogeneous preparations, including potency variability and contamination. Clinicians should prefer GMP-compliant, well-characterized products, use the minimum effective dose and duration, avoid use in active hormone-sensitive or LHCGR-expressing malignancies, and monitor for immunologic or thrombo-angiogenic adverse effects where clinically relevant.

Regulatory and Legal Status#

Summary of available evidence and scope of this answer

• The only directly retrievable evidence in the current context concerns the United States. It documents FDA consumer/press warnings issued in 2011–2012 stating that HCG is not approved for weight loss and that over-the-counter/homeopathic HCG “diet” products are illegal. It also notes safety concerns reported in connection with HCG used for weight loss. No primary EMA, TGA, MHRA, or Health Canada documents could be retrieved in the current evidence set. Therefore, the United States section below is evidence-based; the other jurisdictions cannot be authoritatively summarized here without additional sources.

United States (FDA)

• Legal status and approved indications: HCG is an FDA-approved prescription drug for reproductive/endocrine indications (e.g., triggering ovulation, hypogonadism management), but it is not approved for weight loss. The FDA has explicitly warned consumers and firms about HCG “diet” products.
• Weight-loss/homeopathic HCG: FDA/FTC issued warning letters and consumer communications (2011–2012) stating that products marketed as “homeopathic HCG” for weight loss are illegal and lack evidence of safety and efficacy. The FDA emphasized that HCG is not approved for weight loss and that marketing such OTC/homeopathic products violates federal law.
• Notable recent actions: The 2011–2012 enforcement and consumer alerts are the major actions captured in the present evidence; they frame the current position that HCG diet products are unlawful and unsupported. The article also notes postmarketing reports of thromboembolism with HCG used for weight loss, highlighting safety concerns.

Evidence gaps for EU (EMA), Australia (TGA), UK (MHRA), and Canada

• The current evidence set does not include authoritative regulator documents for these jurisdictions (e.g., EMA product assessments/SmPCs for choriogonadotropin alfa, TGA scheduling/advice on HCG and advertising of weight-loss claims, MHRA prescription-only status and enforcement notices, or Health Canada advisories/NOC or DIN status). As a result, I cannot provide a reliable, fully cited summary for EMA, TGA, MHRA, or Health Canada here.

What would complete the answer

• EU/EMA: summaries of product characteristics for authorized HCG-containing medicines (e.g., choriogonadotropin alfa), and any EMA or national competent authority statements on weight-loss uses.
• Australia/TGA: Poisons Standard scheduling (likely Schedule 4 prescription), TGA advisories/enforcement on HCG “diet” products and advertising, and ART-related approvals.
• UK/MHRA: Prescription-only medicine classification, and any MHRA alerts or enforcement related to HCG sold for weight loss or as homeopathic products.
• Canada/Health Canada: Prescription drug list status, Drug Identification Numbers (DINs) for approved HCG products, and advisories/enforcement actions regarding weight-loss/homeopathic HCG products.

Conclusion

• Based on the evidence available here, FDA’s position is clear: HCG is not approved for weight loss; homeopathic/OTC HCG “diet” products are illegal, and the agency has taken enforcement and issued consumer warnings (2011–2012). Additional regulator-authored documents are needed to accurately characterize current status and any recent changes in the EU, Australia, UK, and Canada.

At-Risk Populations#

Populations at highest risk when using human chorionic gonadotropin (hCG)

Pregnancy and those pursuing pregnancy via fertility treatment

• Why at risk: hCG is the principal trigger for ovarian hyperstimulation syndrome (OHSS) after controlled ovarian stimulation. OHSS is mediated by VEGF-driven vascular permeability, causing third-spacing, hemoconcentration, and a prothrombotic state. Pregnancy itself can worsen or prolong OHSS (late-onset OHSS) and has been associated with higher risks such as pre-eclampsia, preterm delivery, and thromboembolism when OHSS occurs. High ovarian response (e.g., PCOS, high AMH/AFC, high estradiol/mature follicle counts) further elevates risk.
• Practical implications: In high-risk responders, use strategies that avoid or reduce exogenous hCG exposure (e.g., GnRH-agonist trigger, segmentation/freeze-all) and individualize thromboprophylaxis when moderate–severe OHSS is present. Counsel about multiple gestation risk inherent to high response and stimulation.

Cancer patients

• Why at risk (diagnostics): Exogenous hCG administration can yield positive urine/serum hCG tests and confound interpretation in patients monitored with hCG, while some non-trophoblastic malignancies secrete free β-hCG. Clinicians should explicitly document exogenous hCG exposure and use appropriate assay interpretation to avoid misdiagnosis or inappropriate therapy.
• Uncertain risk (tumor stimulation): Our retrieved context did not provide direct evidence or labeling on hCG stimulating androgen‑dependent tumors (e.g., prostate cancer). Although this concern is often raised in practice, we cannot substantiate it from the present sources; decisions should be individualized with oncology input.

Immunocompromised individuals

• Evidence gap: We did not retrieve context that directly quantified injection-related infection risk or preservative (e.g., benzyl alcohol) concerns specific to hCG in immunocompromised patients. General injection-safety principles likely apply, but supporting citations are absent in the current evidence set; this part of the answer is therefore partial.

Patients on anticoagulants (warfarin or DOACs)

• Evidence gap: We did not retrieve context addressing bleeding/hematoma risk with IM or SQ hCG injections in anticoagulated patients or practice guidance to mitigate risk. This part of the answer is therefore partial.

Summary

• Highest demonstrable risk in our evidence pertains to pregnant patients or those undergoing fertility treatment using hCG because of OHSS (and its thrombotic and obstetric sequelae) and to cancer patients from a diagnostic standpoint due to hCG assay confounding. For immunocompromised individuals and those on anticoagulants, we could not locate supporting evidence in the retrieved context; apply standard injection-safety and anticoagulation best practices and consult disease-specific guidelines until more targeted evidence is available.

Risk Mitigation#

For Researchers#

1. Use only from verified, third-party tested sources
2. Follow proper handling and sterility protocols
3. Document all observations carefully
4. Report adverse events

General Precautions#

1. Consult healthcare providers before any use
2. Start with lowest suggested amounts in research protocols
3. Monitor for any adverse effects
4. Discontinue immediately if problems arise

Related Reading#

• HCG overview and research guide
• HCG side effects profile
• HCG research evidence